Evidence map›Paper›PMID 31617564›Full record

ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2019

Cancer-related cognitive impairment: an update on state of the art, detection, and management strategies in cancer survivors.

M Lange, F Joly, J Vardy, T Ahles, M Dubois, L Tron, G Winocur, M B De Ruiter, H Castel

6 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 394 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
394citing papers in PubMed, 18 pooled it
37.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04210778 nacompletednot on this map

Combined Model of Online Remote Interventions for Cancer-Related Cognitive Impairment

TypeinterventionalSponsorHadassah Medical OrganizationRan2018 to 2022Enrolled90ConditionsCognitive Decline, CancerArmsCognitive orientation to daily occupational performance (CO-OP), Computerized Cognitive Training (BrainHQ, posit science)
NCT05504681 recruitingnot on this mapstarted 2021, after this paper: background citation

Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic

TypeobservationalSponsorBaptist Health South FloridaRan2021 to 2032Enrolled200ConditionsNeurocognitive DisordersArmsObservational study
NCT06103318 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Cognitive Rehabilitation and Psychosocial Intervention Through a Stepped Digital Ecosystem in Breast Cancer: A Randomized Clinical Trial.

TypeinterventionalSponsorInstitut Català d'OncologiaRan2024 to 2025Enrolled176ConditionsBreast Cancer, Cognitive DysfunctionArmsICOgnition
NCT06251570 unknown statusnot on this mapstarted 2024, after this paper: background citation

Evaluation of Dual Task Performance and Respiratory Muscle Endurance in Patients With Lung Cancer

TypeobservationalSponsorHacettepe UniversityRan2024 to 2024Enrolled60ConditionsLung CancerArmsEvaluation of Dual Task Performance
NCT06313359 recruitingnot on this mapstarted 2024, after this paper: background citation

Fall Risk and Quality of Life: Influence of Dual Task Performance, Cognition, and Sensorimotor Variables in Individuals With Cancer Treatment Related Peripheral Neuropathy.

TypeobservationalSponsorTexas Woman's UniversityRan2024 to 2026Enrolled40ConditionsPeripheral Neuropathy Due to Chemotherapy
NCT07755839 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

CanCOG® - Cognitive Rehabilitation in Cancer: A Protocol for a Multicenter Pilot Randomized Controlled Trial With Non-central Nervous System Cancer Survivors

TypeinterventionalSponsorAveiro UniversityRan2026 to 2028Enrolled60ConditionsCancer-related Cognitive Impairment, Cancer-related Cognitive Dysfunction, Cancer-related Cognitive Difficulties, Depression and Anxiety SymptomsArmsCanCOG® - Cogntive Rehabilitation in Cancer
3 · Its place in the literature

Who cites it

394 citing papers in PubMed, 18 syntheses or guidelines pooled it, 648 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Efficacy and safety of tACS in older adults with cognitive impairment: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. The effect of exercise on cognitive function in breast cancer survivors: systematic review and meta-analysis of randomized controlled trials.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  11. Pooled it
  12. Cancer-related cognitive impairment in patients with hematologic malignancies after CAR T cell therapy: a systematic review and meta-analysis of prevalence.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  13. The effect of non-pharmacological interventions on cognitive function in cancer: an overview of systematic reviews.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Guideline
  18. Pooled it
  19. Trial
  20. Trial

334 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 6 countries.

M LangeINSERM, U1086, ANTICIPE, 14000 Caen; Clinical Research Department, Centre François Baclesse, 14000 Caen; Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen.
F JolyINSERM, U1086, ANTICIPE, 14000 Caen; Clinical Research Department, Centre François Baclesse, 14000 Caen; Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen; Medical Oncology Department, CHU de Caen, 14000 Caen, France. Electronic address: f.joly@baclesse.unicancer.fr.
J VardyConcord Cancer Centre, Concord Repatriation General Hospital, Sydney, New South Wales; Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
T AhlesNeurocognitive Research Lab, Memorial Sloan Kettering Cancer Center, New York, USA.
M DuboisCancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen; Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen; Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen.
L TronINSERM, U1086, ANTICIPE, 14000 Caen; Cancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen; CHU de Caen, 14000 Caen, France.
G WinocurBaycrest Centre, Rotman Research Institute, Toronto; Department of Psychology, Trent University, Peterborough; Department of Psychology and Psychiatry, University of Toronto, Toronto, Canada.
M B De RuiterDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
H CastelCancer and Cognition Platform, Ligue Nationale Contre le Cancer, 14000 Caen; Normandie University, UNIROUEN, INSERM, DC2N, 76000 Rouen; Institute for Research and Innovation in Biomedicine (IRIB), 76000 Rouen.
Inserm · FRMemorial Sloan Kettering Cancer Center · USThe Netherlands Cancer Institute · NLThe University of Sydney · AUUniversity of Toronto · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundAdvances in diagnostic and therapeutic strategies in oncology have significantly increased the chance of survival of cancer patients, even those with metastatic disease. However, cancer-related cognitive impairment (CRCI) is frequently reported in patients treated for non-central nervous system cancers, particularly during and after chemotherapy.

designThis review provides an update of the state of the art based on PubMed searches between 2012 and March 2019 on 'cognition', 'cancer', 'antineoplastic agents' or 'chemotherapy'. It includes the most recent clinical, imaging and pre-clinical data and reports management strategies of CRCI.

resultsEvidence obtained primarily from studies on breast cancer patients highlight memory, processing speed, attention and executive functions as the most cognitive domains impaired post-chemotherapy. Recent investigations established that other cancer treatments, such as hormone therapies and targeted therapies, can also induce cognitive deficits. Knowledge regarding predisposing factors, biological markers or brain functions associated with CRCI has improved. Factors such as age and genetic polymorphisms of apolipoprotein E, catechol-O-methyltransferase and BDNF may predispose individuals to a higher risk of cognitive impairment. Poor performance on neuropsychological tests were associated with volume reduction in grey matter, less connectivity and activation after chemotherapy. In animals, hippocampus-based memory and executive functions, mediated by the frontal lobes, were shown to be particularly susceptible to the effects of chemotherapy. It involves altered neurogenesis, mitochondrial dysfunction or brain cytokine response. An important next step is to identify strategies for managing cognitive difficulties, with primary studies to assess cognitive training and physical exercise regimens.

conclusionsCRCI is not limited to chemotherapy. A multidisciplinary approach has improved our knowledge of the complex mechanisms involved. Nowadays, studies evaluating cognitive rehabilitation programmes are encouraged to help patients cope with cognitive difficulties and improve quality of life during and after cancer.

Indexed as

Antineoplastic AgentsApolipoproteins EBrain-Derived Neurotrophic FactorCancer SurvivorsCatechol O-MethyltransferaseCognitionCognitive DysfunctionCytokinesExerciseHumansNeoplasmsNeurogenesisPolymorphism, GeneticQuality of LifeAntineoplastic AgentsApolipoproteins EBDNF protein, humanBrain-Derived Neurotrophic FactorCatechol O-MethyltransferaseCytokinesanimal modelcancer patientscancer-related cognitive impairmentcancer treatmentsmanagementof cognitive impairmentneuro-imaging

Identifiers

PMID31617564
PMCPMC8109411
OpenAlexW2982637342

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.